Clinical Trial Update: XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)

View source ↗

Summary

This is a post-approval USA Phase 1 study of the XIENCE V Everolimus-eluting coronary stent system; it has completed enrollment and posted results in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• XIENCE V Everolimus Eluting Coronary Stent System (Everolimus-eluting coronary stent)

Snippet

Sponsor: Abbott Medical Devices | Conditions: Coronary Artery Disease | Status: COMPLETED | Results posted: 2012-11-20